MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
In 2025, the Group reported revenue from sales and services of THB 701.92 million, representing a decrease of THB 128.21 million, or 15.44%, compared with THB 830.13 million in 2024. The net profit attributable to the parent company amounted to THB 131.10 million, decreasing by THB 39.34 million, or 23.54%, from THB 167.09 million in 2024.
The net profit margin in 2025 was 18.19%, a decrease from 19.80% in 2024. This decline was primarily attributable to the unusually high number of patients who accelerated their treatments during the first quarter of 2024, as many couples wished for their children to be born in the Year of the Dragon. Nevertheless, the Company maintained effective cost and expense management, the profit margin to remain at a relatively high level.
Operating Results & Financial Condition
Operating Results & Profitability
Performance
Consolidated | 31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | |
THB million | % | |||
Revenue from sales and services | 830.13 | 701.92 | (128.21) | (15.44) |
Cost of sales and services | (372.86) | (310.72) | 62.13 | (16.66) |
Gross profit | 457.28 | 391.20 | (66.08) | (14.45) |
Unrealised gain on measurement of financial assets measured at fair value through profit or loss | 5.34 | 14.16 | 8.82 | 165.27 |
Other income | 8.24 | 3.44 | (4.80) | (58.30) |
Profit before expenses | 470.86 | 408.80 | (62.06) | (13.18) |
Selling expenses and distribution costs | (68.55) | (74.90) | (6.35) | 9.27 |
Administrative expenses | (184.16) | (170.23) | 13.93 | (7.57) |
Reversal (recognized) of expected credit loss | (1.47) | 0.88 | 2.35 | 159.63 |
Other gain (loss) | 0.56 | 0.01 | (0.55) | (98.15) |
Net gain (loss) from exchange rate | 0.05 | 1.06 | 1.01 | 1994.87 |
Profit before finance costs and income tax | 217.29 | 165.62 | (51.67) | (23.78) |
Finance costs | (3.72) | (3.47) | 0.25 | (6.73) |
Profit before income tax | 213.57 | 162.15 | (51.42) | (24.08) |
Income tax | (49.00) | (34.10) | 14.90 | (30.41) |
Net profit for the period | 164.57 | 128.05 | (36.52) | (22.19) |
Profit attributable to owners of the parent | 167.09 | 131.10 | (35.99) | (21.54) |
Basic earnings per share (Baht) | 0.55 | 0.43 | ||
Revenue from sales and services
For the year 2025, the Company had revenue from sales and services in the amount of THB 701.92 million, decreased by THB 128.21 million or 15.44% compared with the year 2024 with revenue from sales and services in the amount of THB 830.13 million.
The Company's revenue can be classified into 3 main groups as follows: 1) revenue from infertility treatment services (SAFE) 2) revenue from embryo and fetal genetic screening services (NGG) and 3) revenue from aesthetic and wellness business (SWC). Revenue from infertility treatment services is the major revenue of the Company.
Operate by | 31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | ||
THB million | % | ||||
Revenue from infertility treatment services | SAFE | 641.95 | 540.55 | (101.40) | (15.80) |
Revenue from embryo and fetal genetic testing services | NGG | 169.48 | 143.38 | (26.10) | (15.40) |
Revenue from aesthetic and wellness business | SWC | 18.70 | 17.99 | (0.71) | (3.81) |
Total revenue from sales and services | 830.13 | 701.92 | (128.21) | (15.44) | |
Revenue from infertility treatment services
For the year 2025, the Company had income from infertility treatment services in the amount of THB 540.55 million, decreased by THB 101.40 million or 15.80% compared to the year 2024 with revenue from infertility treatment services in the amount of THB 641.95 million. This is a result of a large number of patients rushing to receive treatment in the first quarter of 2024 because they want their children to be born in the Year of the Dragon.
The number of OPU (“Ovum Pick up”) Cycles from 2023 to 2025 is shown in the following graph.


The graph shown that the Company had OPU cycles at 976 cycles for the year 2025, decreased by 210 cycles or 17.70% compared to the year 2024 with the number of OPU cycles at 1,186 cycles, of which 511 cycles from Thai customers and 465 cycles from foreign customers. The income per OPU cycle is equal to THB 0.55 million per an OPU cycle.
Revenue from embryo and fetal genetic testing services
For the year 2025, the Company had revenue from embryo and fetal genetic testing services in amount of THB 143.38 million, decreased by THB 26.10 million or 15.40% compared to the year 2024 with revenue from embryo and fetal genetic testing services in amount of THB 169.48 million. Due to the expansion of IVF in the first quarter of 2024 from a large number of patients rushing to receive treatment in hopes of having children born in the Year of the Dragon, NGG's clients, mostly IVF clinics and hospitals performing IVF from across the country, sent more patients for examinations in the first quarter of 2024.
Revenue from aestheticand wellness business
For the year 2025, the Company had revenue from aesthetic and wellness business in amount of THB 17.99 million, decreased by THB 0.71 million or 3.81% compared to the year 2024 with revenue from aesthetic and wellness business of THB 18.70 million.
Other income and unrealised gain on measurement of financial assets measured at fair value through profit or loss
For the year 2025, the Company had other income and unrealised gains in amount of THB 17.61 million, increased by THB 3.46 million or 24.47% compared to the year 2024 with an amount of THB 14.15 million. The increase was mainly due to the Company’s investment in financial assets measured at fair value through profit or loss of THB 650 million in the year 2025, resulting in the gain.
Cost of sales and services
For the year 2025, the Company had the cost of sales and services in amount of THB 310.72 million, decreased by THB 62.09 million or 16.66% compared to the year 2024 with the cost of sales and services of THB 372.86 million, mainly due to a decrease in the cost of medicines, medical supplies and medical equipment of THB 43.47 million, a decrease in doctor fees of THB 12.75 million, a decrease in depreciation and amortization of THB 3.73 million and a decrease in maintenance expenses and other expenses of THB 3.73 million. This caused the profit margin for the year 2025 increasing from the year 2024.
Gross profit and Gross profit margin
In the year 2025, the Company had gross profit in amount of THB 391.20 million, decreased by THB 66.12 million or 14.46% compared to the year 2024 with gross profit of THB 475.28 million. Meanwhile, the gross profit margin in the year 2025 was 55.73%, increased to the year 2024 at 55.08%
Selling expenses and distribution costs
For the year 2025, the Company had selling expenses and distribution costs in amount of THB 74.90 million, increased by THB 6.35 million or 9.27% compared to the year 2024 with selling expenses and distribution costs in amount of THB 68.55 million. The main reasons were an increase in employee benefit expenses of THB 3.37 million, an increase in advertising and promotional expenses of THB 2.21 million, and an increase in commissions fee of THB 1.13 million.
Administrative expenses
For the year 2025, the Company had administrative expenses in amount of THB 170.23 million, decreased by THB 13.93 million or 7.57% compared to the year 2024 with administrative expenses in amount of THB 184.16 million, mainly due to depreciation and amortization decreased by THB 11.41 million and other expenses decreased by THB 5.44 million.
Finance costs
For the year 2025, the Company has finance costs in amount of THB 3.47 million, decreased by THB 0.25 million or 6.73% compared to the year 2024 with finance costs in amount of THB 3.72 million.
Net profit and Net profit margin
For the year 2025, the Company had net profit attributable to owners of the parent in amount of THB 127.75 million, decreased by THB 39.34 million or 23.54% compared with the year 2024 in amount of THB 167.09 million. Meanwhile, the net profit margin for the year 2025 was 18.19%, decreased from the year 2024 at 19.79%.
Liquidity & Capital Adequacy
Liquidity
Consolidated | 31 December 2024 (THB Million) | 31 December 2025 (THB Million) |
Net cash receipts (payment) from operating activities | 239.90 | 170.59 |
Net cash receipts (payment) from investing activities | (343.70) | (653.29) |
Net cash receipts (payment) from financing activities | (56.10) | (205.18) |
Net increase (decrease) in cash and cash equivalents | (159.90) | (687.87) |
Cash and cash equivalents – opening balance | 1,251.02 | 1,091.12 |
Cash and cash equivalents – closing balance | 1,091.12 | 403.25 |
From changing in cash flows from operating activities, investing activities and financing activities, as of 31 December 2025, the Company had cash and cash equivalents at the end of the year equal to THB 403.25 million with the details of significant changes in cash flows as follows:
Cash flows from operating activities
The Company had net cash from operating activities of THB 170.59 million. Profit from operating activities before changes in working capital equal to THB 196.01 million. Cash received from operations were trade and other current accounts receivable of THB 4.86 million and inventories of THB 17.60 million. While cash used in operations were trade and other current accounts payable of THB 11.67 million, other non-current asset of THB 0.31 million, other current liabilities of THB 0.23 million, employee benefit obligation of THB 0.78 million and income tax of THB 34.88 million.
Cash flow from investing activities
The Company had net cash outflows used in investing activities of THB 653.29 million, mostly from payments for purchase of financial assets measured at fair value through profit of loss of THB 650 million, purchases of building and equipment of THB 3.97 million, restricted deposits at financial institutions of THB 1.00 million and purchase of intangible assets of THB 0.79 million. While receiving THB 2.47 million from interest income.
Cash flow from financing activities
The Company had net cash used in financing activities of THB 205.18 million from repayments for lease liabilities of THB 16.73 million and dividend payment of THB 188.45 million.
Asset Management Capability
Financial position
31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | ||
THB million | % | |||
Assets | 2,006.97 | 1,923.35 | (83.62) | (4.17) |
Liabilities | 216.71 | 196.85 | (19.86) | (9.17) |
Equity | 1,790.25 | 1,726.50 | (63.75) | (3.56) |
Assets
The Company had total assets as of 31 December 2025 equal to THB 1,923.35 million, decreased by THB 83.62 million or 4.17% from 31 December 2024 with total assets of THB 2,006.97 million. The Company's significant assets include cash and cash equivalents, financial assets measured at fair value through profit or loss, building and equipment and right-of-use assets, etc. The details of the changes are as follows.
Consolidated | 31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | |
THB million | % | |||
Current assets | ||||
Cash and cash equivalents | 1,091.12 | 403.25 | (687.87) | (63.04) |
Financial assets measured at fair value through profit or loss | 537.18 | 1,201.35 | 664.16 | 123.64 |
Trade and other current account receivables (net) | 28.06 | 24.08 | (3.98) | (14.18) |
Inventories (net) | 28.06 | 30.83 | (14.96) | (32.68) |
Total current assets | 1,702.15 | 1,659.50 | (42.65) | (2.51) |
Non-current assets | ||||
Restricted deposits at financial institutions | - | 1.00 | 1.00 | 100.00 |
Building and equipment (net) | 143.63 | 121.69 | (21.94) | (15.28) |
Right-of-use assets (net) | 131.89 | 114.03 | (17.86) | (13.54) |
Intangible assets (net) | 10.13 | 8.83 | (1.30) | (12.84) |
Deferred tax assets (net) | 7.64 | 6.46 | (1.18) | (15.42) |
Other non-current assets | 11.54 | 11.85 | 0.31 | 2.73 |
Total non-current assets | 304.82 | 263.85 | (40.97) | (13.44) |
Total assets | 2,006.97 | 1,923.35 | (83.62) | (4.17) |
Cash and cash equivalents
As of 31 December 2025, the Company had cash and cash equivalents in the amount of THB 403.25 million, decreased by THB 687.87 million or 63.04% from the end of 2024 with an amount of THB 1,091.12 million. The changes in cash and cash equivalents, please see additional information in the section cash flow analysis.
Financial assets measured at fair value through profit or loss
As of 31 December 2025, the Company had financial assets measured at fair value through profit or loss in the amount of THB 1,201.35 million, increased by THB 664.16 million or 123.64% from the end of 2024 with an amount of THB 537.18 million from increased investment in financial assets and increased fair value measurement through profit or loss. The financial assets invested by the Company are still government bonds fund and debt securities fund
Trade and othercurrent accounts receivable (net)
As of 31 December 2025, the Company had trade and other current accounts receivable (net) in the amount of THB 24.08 million, decreased by THB 3.98 million or 14.18% from the end of 2024 with an amount of THB 28.06 million.
Inventories (net)
As of 31 December 2025, the Company had inventories (net) in amount of THB 30.83 million, decreased by THB 14.96 million or 32.68% from the end of 2024 with an amount of THB 45.79 million.
Building and equipment (net)
As of 31 December 2025, the Company had net buildings and equipment (net) in amount of THB 121.69 million, decreased by THB 21.94 million or 15.28% from the end of 2024 with an amount of THB 143.63 million due to depreciation.
Right-of-use assets (net)
As of 31 December 2025, the Company had right-of-use assets (net) in amount of THB 114.03 million, decreased by THB 17.86 million or 13.54% from the end of 2024 with an amount of THB 131.89 million due to depreciation.
Liabilities
The Company had total liabilities as of 31 December 2025 equal to THB 196.85 million, decreased by THB 19.86 million or 9.17% from 31 December 2024 with total liabilities of THB 216.71 million. The main liabilities of the Company are trade and other current account payables, lease liabilities, income tax payable, other current liabilities, employee benefit obligations and provision for decommissioning of fixed assets. The details of the changes are as follows.
Consolidated | 31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | |
THB million | % | |||
Current liabilities | ||||
Trade and other current accounts payable | 82.19 | 71.34 | (10.86) | (13.21) |
Current portion of lease liabilities (net) | 13.93 | 14.46 | 0.53 | 3.81 |
Current corporate income tax payable | 15.05 | 12.25 | (2.80) | (18.62) |
Other current liabilities | 1.63 | 1.40 | (0.23) | (14.04) |
Total current liabilities | 112.80 | 99.45 | (13.36) | (11.84) |
Non-current liabilities | ||||
Lease liabilities (net) | 61.12 | 46.66 | (14.46) | (23.66) |
Employee benefit obligations | 25.05 | 32.33 | 7.27 | 29.04 |
Provision for decommissioning | 17.74 | 18.41 | 0.68 | 3.83 |
Total non-current liabilities | 103.91 | 97.40 | (6.51) | (6.26) |
Total liabilities | 216.71 | 196.85 | (19.86) | (9.17) |
Trade and other current accounts payable
As of 31 December 2025, the Company had trade and other current accounts payable in the amount of THB 71.34 million, decreased by THB 10.86 million or 13.21% from the end of 2024 with an amount of THB 82.19 million.
Current corporate income tax payable
As of 31 December 2025, the Company had income tax payable in the amount of THB 12.25 million, decreased by THB 2.80 million or 18.62% from the end of 2024 with an amount of THB 15.05 million.
Lease liabilities (net)
As of 31 December 2025, the Company had lease liabilities in the amount of THB 61.12 million, decreased by THB 13.93 million or 18.56% compared to the end of 2024 with an amount of THB 75.05 million. Lease liabilities arise from the Company has entered into lease agreements for building and land used in business operations.
Employee benefit obligations
As of 31 December 2025, the Company had employee benefits obligations in the amount of THB 32.33 million, increased by THB 7.28 million or 29.04% from the end of 2024 with an amount of THB 25.05 million. The employee benefit obligations of the Company comprise retirement benefits and other long-term employee benefits. The Company has obligations for compensation to employees upon retirement under labor law and according to other employee compensation programs. The Company treats this compensation as a defined benefit plan for employees that an independent expert has assessed such obligations based on actuarial principles.
Provision for decommissioning
As of 31 December 2025, the Company had a provision for decommissioning of fixed assets in the amount of THB 18.42 million, increased by THB 0.68 million or 3.83% compared to the end of 2024 with an amount of THB 17.74 million.
Equity
The Company had total equity as of 31 December 2025 equal to THB 1,726.50 million, decreased by THB 63.75 million or 3.56% from 31 December 2024 with total equity of THB 1,790.25 million due to the profit decreased and the payment of dividends. The details of the changes are as follows.
Consolidated | 31 December 2024 (THB million) | 31 December 2025 (THB million) | Increased (Decreased) | |
THB million | % | |||
Equity | ||||
Issued and fully paid-up share capital | 303.95 | 303.95 | - | - |
Premium on share capital | 1,382.23 | 1,382.23 | - | - |
Discount from business combination under common control | (178.29) | (178.29) | - | - |
Changes in equity interest from Investments in subsidiaries | 2.13 | 2.13 | - | - |
Retained earnings - Appropriated | 30.39 | 30.39 | - | - |
Retained earnings - Unappropriated | 236.36 | 175.66 | (60.70) | (25.68) |
Equity attributable to owners of parent | 1,776.78 | 1,716.09 | (60.70) | (3.42) |
Non-controlling interests | 13.47 | 10.41 | (3.06) | (22.69) |
Total equity | 1,790.25 | 1,726.50 | (63.75) | (3.56) |
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
1) Changes and compliance with government policies.
The Group’s business operations are regulated by various agencies, including the Ministry of Public Health. These regulations encompass standards for assisted reproductive technology services in accordance with the Protection of Children Born from Assisted Reproductive Technologies Act, B.E. 2558 (2015) and/or the requirements of other government entities that have the power to oversee the licensing and compliance standards necessary for the Group's business operations. To maintain and renew licenses, the Group must strictly comply with the laws, rules, and regulations, as well as many prescribed conditions. However, in the past, the Group consistently adhered to the prescribed standards and maintained the licenses required for its business operations without any instances of license revocation. Furthermore, in 2017, the government formulated a strategic plan to develop Thailand into an internationally recognized center for healthcare services (Medical Hub) over a 10-year period (2017 to 2026). This plan aimed to develop four key pillars, namely the Wellness Hub, Medical Service Hub, Academic Hub, and Product Hub. These developments have had a positive impact on the Group and provided an opportunity to generate income by providing infertility treatment services, particularly for foreign nationals.
2) Competition in the infertility treatment service business
Currently, the business of providing infertility treatment services tends to be more intensely competitive. As the incumbent operators improve their service quality and increase their reputation. And as new operators ARE gradually entering the market, causing the market share to be taken from the existing operators. As a result, there is an awareness of service competition and the use of pricing policies to attract customers. In addition, the impact of trade and service liberalization under the agreement of the ASEAN Economic Community (AEC) may result in new competitors within ASEAN countries expanding their service scope into Thailand. These competitive factors may inevitably affect the Company. However, when compared to other infertility treatment centers in the market, the Group has many competitive advantages. Both in terms of the long-established reputation, location, as well as the quality and modern service standards of the Group.
3) Expansion of Fertility Tourism
The fertility tourism market continues to experience continuous growth due to the easing of the Covid-19 pandemic situation and the increasing demand for children among Chinese individuals. This growth is further supported by China's official announcement on 31 May 2021, regarding the cancellation of the one-child policy and the implementation of a new policy allowing couples to have up to three children. Furthermore, data from the Centers for Disease Control and Prevention (CDC) in the United States reveals an increasing trend in pregnancy among women aged 35 and over. According to the latest data in 2018, the birth rate for women in this age group in the United States was 65.3 (person) out of 1,000 female population of the same age, representing a 13.8 percent increase from 2008 when it was 57.4 (person) out of 1,000 women of the same age. This trend aligns with the pregnancy pattern among women aged 35 and over in Thailand. In 2018, the birth rate for women aged 35 and over was 40.5 (person) out of 1,000 female population of the same age, representing a 14.7% increase from 2008 when it was 35.3 (person) out of 1,000 women of the same age. Pregnancy at an older age carries an increased risk of miscarriage and genetic abnormalities. Therefore, infertility treatment technology can help mitigate these risks. According to a research by Precedence Research, the medical tourism industry is projected to have a market value of USD 300 billion by 2032, at a CAGR of 11% from 2022 to 2032.The Asia-Pacific market is poised to become the world's most valuable market, while Europe is expected to be the fastest-growing market. Key destinations for fertility tourism among foreigners in the Asia-Pacific region include India, Malaysia, Thailand, Japan, and Australia. Thailand is a prominent destination for fertility tourism among foreigners. An important highlight of medical services in Thailand is the affordability of healthcare expenses compared to other countries. This is in addition to the renowned reputation of doctors, high quality and standards of treatment, and excellent services provided by doctors and nurses. According to the Medical Tourism Association, the average cost of infertility treatment in Thailand is USD 7,860, which is 49% cheaper than the United States. In addition, Thailand offers advantages in terms of cleanliness and safety standards, digital connectivity, continuous infrastructure development, and relatively flexible policies that attract foreigners. These factors play a crucial role in the future growth of the infertility tourism market and have a positive impact on the Group. The increased revenue from infertility treatment services, which is the main source of income for the Group, is influenced by these factors.

